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IMAGING FOR BEST OUTCOMES IN STRUCTURAL HEART INTERVENTIONS SPECIAL ISSUE

Imaging for Native Mitral Valve Surgical
and Transcatheter Interventions
Livia L. Gheorghe, MD,a,b Sara Mobasseri, MD,c Eustachio Agricola, MD,d Dee Dee Wang, MD,e Federico Milla, MD,c
Martin Swaans, MD,a Dimosthenis Pandis, MD, MSC,f David H. Adams, MD,f Pradeep Yadav, MD,c Horst Sievert, MD,g
Gorav Ailawadi, MD,h Paul Sorajja, MDi

ABSTRACT
There has been rapid progress in transcatheter therapies for mitral regurgitation. These developments have elevated the
need for the imager to have a core understanding of the functional mitral valve anatomy. Pre- and intraoperative
echocardiography for surgical mitral valve repair for mitral regurgitation has deﬁned contemporary interventional imaging in many ways. The central tenets of these principles apply to interventional imaging of transcatheter mitral valve
interventions. However, the heightened emphasis on procedural planning and procedural imaging is one of the new
challenges posed by transcatheter interventions. This need for accurate and reliable information has required the imager
to be agnostic to the imaging modality. Cardiac computed tomography has become critical in procedural planning in this
new paradigm. The expanded use of pre-procedural cardiac magnetic resonance to quantify mitral regurgitation and
characterize the left ventricle is another illustration of this newer approach. Other illustrations of the new world of
interventional imaging include the expanded use of 3-dimensional (3D) transesophageal echocardiography and real-time
fusion of echocardiography and ﬂuoroscopy images. Imaging data are also the basis for computational modeling, 3D
printing, and artiﬁcial intelligence. These technologies are being increasingly explored to improve therapy selection and
prediction of procedural outcomes. This review provides an update of the essentials in present interventional imaging for
surgical and transcatheter interventions for mitral regurgitation. (J Am Coll Cardiol Img 2021;14:112–27) © 2021 by the
American College of Cardiology Foundation.

M

itral regurgitation (MR) is the most preva-

therapies for patients with symptomatic degenera-

lent form of valve disease in subjects >75

tive, severe MR. More recently, transcatheter thera-

years of age in the Western world (1,2).

pies for MR have been developed, aimed primarily

Surgical repair (when the likelihood of successful

at providing an alternative to surgery in those with

repair is high) and replacement are the standard

symptomatic severe primary MR and high surgical
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risk. Transcatheter therapy is also indicated in those

left coronary cusps of the aortic valve and the

ABBREVIATIONS

with greater than moderate-to-severe functional MR

left border of the MA. The posteromedial or

AND ACRONYMS

and who continue to have symptoms of heart failure,

right trigone joins the membranous septum,

despite optimal guideline-mandated medical therapy

MA, tricuspid annulus, and noncoronary cusp

and when coronary revascularization and cardiac syn-

of the aortic valve. Other key facts about the

chronization therapy have been included or excluded

annulus for the imager are summarized

as management options (3,4). Imaging is critical to

below.

the success of these surgical and transcatheter thera-

Key points.

pies, and it requires an essential understanding of the

 The projected annular shape in 3D imaging

normal mitral valve (MV) anatomy and how it is

changes throughout the cardiac cycle,

altered in disease states.

reﬂecting the dynamic changes. It is seen

ESSENTIAL SURGICAL, FUNCTIONAL AND
IMAGING ANATOMY

synchrony to open during diastole and close in systole within the high-pressure systemic environment.
The competent functioning of the MV depends on the
coordinated interaction of its anatomic components,
namely, the annulus, the 2 leaﬂets, the left atrium
(LA), the left ventricle (LV), the papillary muscles,
and the chordae tendinae (5–8). The following section
provides a focused review of the essential surgical
anatomy

in

the

anteroposterior

diameter

(Video 1, Slides 6 to 8).

The MV is composed of several structures working in

functional

posteromedial diameter (which increases)
than

for

the

interventional

imager.
THE ANNULUS AND AORTOMITRAL CONTINUITY.

The mitral annulus (MA) is a concept rather than a

CFD = color ﬂow Doppler
CMR = cardiac magnetic
resonance

CS = coronary sinus
CT = computed tomography

most prominently in the anterolateral-

and

113
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 The upper limits of systolic dimensions of

GCV = greater cardiac vein
MA = mitral annulus
MV = mitral valve
TEE = transesophageal
echocardiography

TMVR = transcatheter mitral
valve replacement

TTE = transthoracic
echocardiography

the normal annulus are a perimeter of
125 mm and an area 675 mm 2 (Video 1, Slide 8)
(Acuson SC2000, eSie Valves, Siemens SC, Munich,
Germany) (9). Normal values vary based on the
vendor-speciﬁc algorithm, but these numbers
represent the upper limit of normal regardless of
the vendor.
 Compared to diastole, the annular area decreases
by w25% in peak systole, and the perimeter reduces by w13%. Atrial contraction is responsible
for more than 90% of annulus narrowing, whereas
the systolic ventricular contraction is responsible
for the remaining 10%. (9)

deﬁned anatomic structure. The junctional zone,

 Annular dynamics play a key role in the patho-

which separates the LA and the LV represents the

genesis of primary and secondary MR (Video 1,

concept of the MA. The virtual MA is ventricular to the

Slides 10 and 11). The sizes (perimeter and area)

mitral leaﬂet attachment and w2 mm external to the

and the saddle shape (nonplanarity) of the annulus

visible mitral leaﬂet attachment (Video 1, Slide 2) (9).

at baseline and the changes that occur during sys-

It is not a rigid ﬁbrous ring. During the cardiac cycle,

tole are predictors of recurrent MR after trans-

the MA changes its shape, alternating between a kid-

catheter MV leaﬂet repair (MitraClip; Abbott

ney shape and a "D”- shaped conﬁguration. The

Laboratories, Abbott Park, Illinois). A larger, planar

change in shape is due to the transverse diameter

(loss of saddle shape) annulus at baseline, and

becoming greater than the anteroposterior diameter

relatively adynamic annulus during systole predict

secondary to LV contractility (Video 1, Slide 3).

recurrent MR (10–12).

Moreover, the MA has a three-dimensional (3D)

 The intertrigonal distance is used to size the mitral

saddle-shaped conﬁguration (Video 1, Slide 4) with

ring during surgical MV repair (13). This distance is

the highest point along the anterior annulus toward

typically smaller than the intercommissural dis-

the LA and the lowest point at the level of the

tance (Video 1, Slide 4).

commissure. Posteriorly, the annulus is a band of

 Whereas the anterior part of the annulus is virtu-

ﬁbrous tissue at the attachment of the posterior

ally immobile, the posterior annulus moves toward

leaﬂet. This is the segment that is often prone to dilate

the apex in systole, contributing to the late systolic

in the MR or to calcify in a degenerative process.

increase of the aortic oriﬁce, and effective sealing

Anteriorly, there is no actual annulus. Instead, the

of the mitral oriﬁce by the leaﬂet and increase in

aortomitral curtain extends from the aortic annulus to

the aortomitral angle. In diastole, there are recip-

the base of the anterior MV leaﬂet (Video 1, Slide 4).

rocal movements with a signiﬁcant increase of the

There are 2 triangular ﬁbrous regions at each end of

mitral area, recovering the almost circular shape

the base of the anterior MV leaﬂet (Video 1, Slide 5).

and decrease of the aortomitral angle, which

The anterolateral or left trigone is contiguous to the

maximizes LV ﬁlling (Video 1, Slide 9).
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T A B L E 1 Scheme for Selection of Surgical or Transcatheter Mitral Valve Therapy Based on Anatomical Considerations

Transcatheter Therapy*
Pathology

Surgical Repair

Repair

Replacement†

þþþ

þ/þþ
Leaﬂet or annuloplasty

þþ

þþþ
Beating heart artiﬁcial chord
implantation or leaﬂet repair
with annuloplasty with CPB

þþþ/þþ
Leaﬂet, artiﬁcial chordal
implantation, annuloplasty



Anterior leaﬂet prolapse (Type II)

þþþ/þþ

þþ/þþþ
Leaﬂet, artiﬁcial chordal
implantation, annuloplasty

þ/þþ‡

Forme fruste Barlow MV
(Multisegment prolapse) (Type II)

þþþ/þþ

þþ
Leaﬂet, artiﬁcial chordal
implantation, annuloplasty

þ/þþ‡

Barlow MV (Type II)

þþþ/þþ

þþ
Leaﬂet, artiﬁcial chordal
implantation, annuloplasty

þ/þþ‡

Barlow MV with RCT (Type II)

þþþ/þþ

þþ
Leaﬂet, artiﬁcial chordal
implantation, annuloplasty

þ/þþ‡

P1 prolapse with RCT (Type II)

þþþ

þþ/þþþ
Leaﬂet, artiﬁcial chordal
implantation

þþ/þþþ

Medial commissural prolapse

þþþ

/þ
Leaﬂet, artiﬁcial chordal
implantation

þþ/þþþ

Lateral commissural prolapse

þþþ

/þ
Leaﬂet, artiﬁcial chordal
implantation

þþ/þþþ

Medial commissural prolapse with
perforation

þþþ

/þ
Leaﬂet

þ/þþþ

Annular dilation (Type I)

P2 prolapse with RCT (Type II)

Surgical and Imaging Anatomy

Continued on the next page
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T A B L E 1 Continued

Transcatheter Therapy*
Pathology

Surgical and Imaging Anatomy

Surgical Repair

Repair

Replacement†





þþþ
Surgical

þþ/þþþ

þþþ/þþ
Leaﬂet or annuloplasty or
ventricular repair system

þþþ

Barlow MV with cleft and leaﬂet
calcium

þþþ

þþ/þþþ||
Leaﬂet

þþþ/þþ

A3 Prolapse, MAC, and restricted
posterior MV leaﬂet

þþ

þþþ/þþ||
Leaﬂet

þþþ/þþ

Rheumatic MS (Type IIIA)

Restricted posterior leaﬂet
(Type IIIB)

*Currently only transcatheter leaﬂet edge-to-edge devices (MitraClip and PASCAL) are approved for treatment of symptomatic severe Type II and Type III B Thus, the role of transcatheter therapies in this
table represents a proposal based on results of small EFS and the current understanding of the technologies in the treatment of MR. This is will continue to be modiﬁed based on data from ongoing and future
trials. †All replacement devices are undergoing clinical trials and are unapproved at the present time. ‡TMVR in these anatomies have not been speciﬁcally studied, especially regarding potential LVOT
obstruction and the role of anterior MV leaﬂet laceration/reduction (Lampoon) procedure in preventing this complication. ||Annular calcium is not necessarily prohibitive, but leaﬂet calcium at the grasp area
is prohibitive.
– ¼ not recommended or not possible; þ ¼ not optimal, beneﬁt not known; þþ ¼ may be considered, may be beneﬁcial and procedural success depends on additional factors (e.g., ﬂail gap and width in the
case of Type II abnormalities or extent of posterior leaﬂet tethering and length of the posterior leaﬂet length in Type III B abnormality); þþþ ¼ optimal choice, currently being evaluated in EFS or RCT;
CPB ¼ cardiopulmonary by-pass; EFS ¼ early feasibility studies; MAC ¼ mitral annular calciﬁcation; MR ¼ mitral regurgitation; MS ¼ mitral stenosis; MV ¼ mitral valve; RCT ¼ randomized clinical trials;
RCT ¼ ruptured chordae tendinae; TMVR ¼ transcatheter mitral valve replacement.

 The normal aortomitral angle is w120 in peak

respective commissures (Video 1, Slide 1). Each leaﬂet

systole. The narrower angle in systole may pre-

is anchored at the base to the annulus (anterior leaﬂet

dispose to left ventricular outﬂow tract (LVOT)

to approximately one-third and the posterior leaﬂet

obstruction

to the other two-thirds of the perimeter of the

post-transcatheter

mitral

valve

replacement (TMVR) and systolic anterior motion

annulus). The leaﬂets are attached at the free borders

(SAM) of the anterior mitral leaﬂet post-surgical

to the subvalvular apparatus (the chordae tendineae).

MV

LVOT

Moreover, both leaﬂets have 2 distinct zones: the

 The aortomitral curtain plays an essential role,

thinner and appears translucent, and the coaptation

ensuring both aortas and MVs to work in synchrony

zone, which is thicker and rough, along the free edge

so that the reciprocal changes in the mitral and

where multiple chordae tendinae are attached on the

aortic annular areas maximize left ventricular (LV)

ventricular side. The thickness of normal leaﬂets is

ﬁlling

systole,

approximately 1 to 2 mm, and with aging, it may

respectively. From end-diastole to end-systole,

measure 4 to 5 mm in thickness. Unlike the anterior

there is a 15% reduction in mitral annular area

leaﬂet, the posterior leaﬂet has typically 2 in-

accompanied by approximately 25% increase in

dentations in its free border that permit it to open

aortic annular area, which facilitates LV emptying

fully during diastole to maximize LV ﬁlling. These 2

(Video 1, Slide 9) (17).

indentations separate the surface of the posterior

repair

with

consequent

dynamic

obstruction (14–16).

and

ejection

atrial zone closer to the base of the leaﬂets, which is

in

diastole

and

leaﬂet into lateral (P1), middle (P2), and medial (P3)
LEAFLETS AND COMMISSURES. The MV consists of 2

scallops. The corresponding facing portions of the

leaﬂets labeled anterior (aortic) and posterior (mural)

anterior leaﬂet are called A1, A2, and A3, even if no

with similar surface areas and separated by their

scallop can be identiﬁed in the anterior leaﬂet (9,18).
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T A B L E 2 Role of Imaging for Planning Transfemoral Edge-to-Edge Leaﬂet Repair

Favorable anatomical and hemodynamic markers

 The A2 height is used to size the ring during surgical MV repair and for planning TMVR, where it is
an important determinant of LVOT obstruction

 A2/P2 prolapse
 Flail A2/P2 prolapse and ﬂail gap/width <10 and 15 mm, respectively
 Single central jet or jet has a dominant central location

post-TMVR (19). The typical A2 height is approximately 23 mm (Video 1, Slide 12).
 Functionally, the anterior leaﬂet, as a continuation

 Left ventricular cavity size <65mm
 Trans-septal crossing height to mitral annulus plane >4cm

of the aortic-mitral curtain, participates passively

 Nontethered leaﬂets with leaﬂet length $10mm

in the mechanism of closure of the valve. The

 Baseline mitral valve mean gradient <3 mm Hg

posterior annulus contracts, determining the scal-

Predictors of a challenging procedure (not prohibitive or contraindication) and suboptimal
procedural outcome

lop’s coaptation, and moves toward the anterior
leaﬂet with complete valve closure and correct

 Commissural prolapse

apposition of both leaﬂets.

 Barlow’s mitral valve disease

 In diastole, the open anterior leaﬂet divides the LV

 Anterior leaﬂet prolapse with ruptured chordae tendinae
 Multiple prolapse segments far from each other along grasping plane
 Multiple segment ﬂail

into the inﬂow and outﬂow regions. The posterior
leaﬂet is related to the muscular portion of the free

 Cleft at or adjacent to the leaﬂet grasp area

posterior LV wall. Therefore, in systole, it is

 s/p Surgical mitral valve repair/annular ring or band
 Severe mitral annular calciﬁcation, with <5 mm of leaﬂet available for grasp
 Leaﬂet or chordal calciﬁcation within the grasp area

exposed to maximum stress, especially the P2
scallop; hence, it prolapses more commonly than
other scallops.

 Mobile posterior leaﬂet length <7 mm
 Tethering height >11 mm
 Mitral valve area (planimetered) <4 cm2 and MV mean gradient 4-5 mm Hg

PAPILLARY MUSCLES AND CHORDAE TENDINAE.

 Small left atrial size (especially medial-lateral diameter <3.7 cm)

The relative positions of the papillary muscles to the

 Lipomatous interatrial septum, patent foramen ovale, or previous septal surgical or
device closures

mitral commissures are used to label them. The

 Large mitral valve annulus: 3D MV area >140 cm 2

muscles are inserted into the LV wall approximately

 A dynamic mitral valve annulus and mitral annular height <7 mm
 Left ventricular size >65 mm or end-diastolic volume >120 ml/m

anterolateral (AL) and posteromedial (PM) papillary

2

Contraindications

one-third from the apex (Video 1, Slide 13). Each
papillary muscle is associated with a single head (AL

 Carpentier IIIA abnormality, e.g., rheumatic mitral valve disease

typically) or single muscle with multiple heads (PM

 Left atrial/Left atrial appendage clot

typically). The chordae connect both papillary mus-

 Calciﬁcation of leaﬂets at the grasp area

cles to both leaﬂets. Usually, the AL muscle is sup-

 Mitral valve mean gradient >5 mm Hg or mitral valve area <3 cm 2

plied by the left anterior descending and 1 or more

 Severe right ventricular dysfunction and pulmonary hypertension unrelated to valve
disease
 Interatrial septal occluder device that is unable to be crossed with traditional transcatheter electrocautery or balloon septostomy methods

branches of the circumﬂex coronary arteries. A single
branch of the circumﬂex or the right coronary artery,
depending on coronary artery dominance, supplies
the PM papillary muscle. Therefore, the PM muscle is

MV ¼ mitral valve.

more susceptible to coronary ischemia.
The chordae tendinae are ﬁlament-like structures
that connect the ventricular surface and free border
Key points.

of the leaﬂets to the papillary muscles. The number

 The leaﬂets’ surfaces, taken together, are 2.5 times

and length of chords

vary

depending

on

the

the area of the valvular oriﬁce. In systole, the

morphology and length of the papillary muscles. They

height of the rough coaptation surface is approxi-

are classiﬁed according to the point of insertion be-

mately 7 to 10 mm. It ensures competent sealing of

tween the free border and the leaﬂet base. Primary

the mitral oriﬁce, providing an “overlapping

(marginal) chords are attached to the free edge of

reserve” or a “coaptation reserve” in the annular

both leaﬂets’ rough zone, and their attachment to the

dilation.

papillary muscle is often bifurcated or trifurcated.

 The length of the anterior leaﬂet at the mid-portion

Secondary chords are attached to the ventricular

(A2) is, on average, 23 mm, and similarly, the

surface of the leaﬂets in the region of the rough zone.

lengths of the middle P2, P3, and P1 scallops are

This rough zone is located approximately at the mid-

approximately 14, 10, and 9 mm, respectively. (9)

portion of the leaﬂets. The tertiary chords are found

 The P2 length >20mm increases the risk of post-

in the mural (posterior) leaﬂet and attach directly to

operative SAM, hence it needs to be reduced dur-

the ventricular wall. The PM muscle gives rise to

ing surgical MV repair.

chords attached to the medial one-half of both leaﬂets
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and the AL muscle to the rest. Also, each indentation
of the posterior leaﬂet receives up to 3 fan-like

T A B L E 3 Imaging Guide to Planning Transapical TMVR

Annulus size

chordae (9,20).

 Used to size the THV

Key points.
 The lengths of the papillary muscles are variable
depending on the morphology and attachment,

 Perimeter, A-P and L-M diameters are used to size the THV
 Oversizing factor depends on the type of THV
Anterior leaﬂet size

and the distance from the head to the mitral oriﬁce

 Length determines the potential for LVOT obstruction

is approximately 15 to 25 mm (9).

 Length >2.5 cm increases the risk of LVOT

 The lengths of the chordae vary but typically range

 Anterior leaﬂet area by CT or 3D TEE >8 cm 2 increases the risk of LVOT obstruction
Septal wall thickness

from 10 to 15 mm (9).
 The A2 and P2 regions may be supported by thick
chords forming an arcade of supporting chords or

 Upper septal wall thickness $2cm may increase the risk of LVOT obstruction
 Septal thickness $1.5 cm can increase the risk of LVOT obstruction if SALP >400 mm 2
LVOT area and Neo- LVOT area

by chords attached to the intermediate papillary or

 Native LVOT area <1.8 cm 2 signiﬁcantly increases the risk of LVOT obstruction

by chords crossing the midline.

 Native LVOT area <2.0 cm 2 increases risk of LVOT obstruction in the presence of increase upper septal wall thickness and/or long anterior mitral valve leaﬂet

LEFT ATRIUM AND LEFT VENTRICLE. The LA and the

LV are directly involved in optimal functioning of the
mitral apparatus. During its contraction, the LA determines the narrowing of the MA, and the LV participates actively in the posterior leaﬂet movement.

 Neo-LVOT area is based on the type of THV and simulation of valve positioning in
volumetric CT or 3D TEE
Aorto-mitral angle
 A narrow angle (#110 ) between LVOT/Aortic annulus and mitral annular plane predisposes to LVOT obstruction
Left ventricular and atrial size

Any condition which alters these 2 structures may

 Small chamber sizes may adversely affect the positioning and stability of THV

lead to valve malfunction and MR.

 LVEDD <3.5 cm or LV ESV <12 ml/m2 or LA size <22 ml/m 2 are all indicators of potential procedural problems and suboptimal outcome

ABNORMAL

MV

ANATOMY. There

are

different

mechanisms by which MR may occur. Carpentier’s
functional classiﬁcation is the most widely used tool

Papillary muscle location and chordae tendinae
 Anteriorly displaced papillary muscle with consequent abnormal course of the chordae
increase the risk of LVOT obstruction

to describe the MR. Class Type I describes normal

 Apical location of the papillary muscle may preclude or increase the complexity of
transapical access

leaﬂet motion. Type II describes excessive leaﬂet

 Aberrant anterior chordae also increase the risk of LVOT obstruction

motion above the annular plane, usually the result of
degenerative disease. Type III describes leaﬂet restriction. Type IIIA, where the restriction occurs
throughout the cardiac cycle (if, in systole and dias-

A-P ¼ anterior-posterior; CT ¼ computed tomography; LA ¼ left atrium; LV ESV ¼ left ventricle end systolic
volume; LVEDD ¼ left ventricle end diastolic diameter; LVOT ¼ Left ventricular outﬂow tract; L-M ¼ lateralmedial; SALP ¼ septal-anterior leaﬂet product (basal septal thickness x anterior leaﬂet length);
TEE ¼ transesophageal echocardiography; THV ¼ transcatheter heart valve.

tole; usually the result of rheumatic valve disease,
collagen-vascular disease, or radiation therapy to the

for the selection of surgical versus transcatheter

chest among other causes), and Type IIIB, where the

repair or replacement therapy based on these

leaﬂet restriction is only in systole (usually the result

anatomic considerations in shown in Table 1.

of regional or global wall motion abnormalities of the

PROCEDURAL

LV). Comprehensive transesophageal echocardiogra-

(degenerative MV disease). The role for pre-procedural

phy (TEE) using 2D, 3D, or color-ﬂow Doppler (CFD)

imaging

is

PLANNING.

centered

Surgical

around

a

MV

repair

comprehensive

imaging is standard when evaluating MV pathology
and the mechanism of MR. Video 2 shows examples of
surgical and 3D TEE anatomy of Type II and Type IIIB

T A B L E 4 Relative Usefulness of Imaging Modalities to Plan TMVR

abnormalities of the MV. However, MR may occur due
to more than one abnormality; hence, the conventional concept of Carpentier’s classiﬁcation of MV

Annulus
Anterior leaﬂet length

2D TEE

3D TEE

CT

Computational Modeling
3D Printing (66)

þ

þþþ

þþþ

þþþ

þþ

þþ

þþþ

þþ

þ

þþþ

CMR

disease in MR needs a more contemporaneous inter-

Chordae location

þþþ

þ

þþþ

þþ

þ

pretation in the context of selecting patients for

Papillary muscle location

þþ

þþ

þþþ

þþþ

þþþ

transcatheter interventions and device interactions

Left ventricular and atrial size

þþ

þ

þþþ

þþþ

þþþ

with the anatomy. Mixed MV disease (Video 2) is

LVOT and neo-LVOT size

þ

þþ

þþþ

þþþ

þþ

more common than previously described. Thus, it is

Aorto-mitral angle

þ

þþþ

þþþ

þþþ

þ

important to include all mechanisms of MR in each

Upper septal thickness

þþþ

þþ

þþþ

þþþ

þþþ

patient in addition to categorization based on classic
Carpentier’s classiﬁcation. The latter emphasizes
leaﬂet motion, but leaﬂet anatomy is equally impor-

þ ¼ not useful, should not be relied upon; þþ ¼ not optimal, but an option when other methods not possible or
available; þþþ ¼ optimal modality, recommended modality; 2D TEE ¼ 2-dimensional transesophageal echocardiography; 3D TEE ¼ 3-dimensional transesophageal echocardiography; CMR ¼ cardiac magnetic resonance;
CT ¼ computed tomography; LVOT ¼ left ventricular outﬂow tract.

tant in the selection of appropriate therapy. A scheme
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T A B L E 5 Procedural Imaging Guide for Transfemoral Edge-to-Edge Leaﬂet Repair (MitraClip and PASCAL Devices)

Step

Tools

Tips

Baseline imaging

 2D and 3D TEE

 Factors listed in Tables 2 and 3 and standard views of the MV and the LV
 VTI of the PW of the LVOT from 2D TEE transgastric view as an estimate of LV
stroke volume
 3D CFD to compute aortic and mitral stroke volumes from which RV and RF
may be calculated.

Safe and optimal site of trans-septal
puncture and placement of the SGC

 2D TEE bicaval view (90 -120 ),
superior-inferior orientation;
 2D TEE short-axis view (30 -45 )
anteroposterior orientation;
 2D TEE, 4-chamber view (0 -20 ),
determines the height above the
MV;
 X-plane imaging (0  and 90 -120  )
to guide placement of SGC in the
LA;
 3D TEE to advance the SGC in the
LA
 2D TEE/ EchoNavigator with 3D
fusion†

 Sharp tenting in both views should be seen prior to the puncture
 Localization: superiorly and posteriorly in the interatrial septum with a
height of 4-4.5 cm (from the sharpest tent to the mitral annulus)*
 If the trans-septal puncture was not optimal consider repuncture to facilitate
proper orientation of the device delivery sheath/system relative to the mitral
coaptation plane; avoid PFO.
 The SGC is advanced over the stiff wire (seen with 3D images) and its dilator
is removed when the SGC is w2 cm across the IAS.

Safe steering of the CDS within the LA
and its alignment perpendicular to
the mitral coaptation plan

 2D TEE, 4 chamber view
 2D TEE Intercommissural view
(60 ) for medial-lateral and LVOT
views (135  -150  ) for
anteroposterior orientation
 3D TEE LA view/en face MV view
 Fluoroscopy

 Follow the device tip as it navigates the LA from a superior location close to
the ostia of the LUPV to the coumadin ridge and then towards the MV.
 Visualize the SGC tip in the LA (seen as a “double-band” on 2D TEE) by
pushing the TEE probe tip down in the esophagus and pulling it up to locate
the clip tips.
 Check perpendicularity in 3D TEE en face MV view
 Check the path of device by using X-plane

Adequate leaﬂet insertion for creation of
the tissue bridge

 2D CFD
 2D TEE Inter-commissural view
(60 ) for medial-lateral, and LVOT
views (135  -150  ) for
anteroposterior orientation
 3D TEE LA view/en face MV view
 Fluoroscopy

 Once the perpendicularity is checked and the proper position is found using
CFD, the clip arms (closed to 60  ) are advanced into the LV, which should be
clearly visualized in the LVOT plane below the MV
 Re-assess perpendicularity of the clip arms or the paddles when the device is
in LV by either 3D TEE LA view/en face MV view and turning down the gain or
2D TEE transgastric view of the MV
 For leaﬂet grasping, 2D LVOT view is used to guide the slow withdrawal of
the device delivery system to the MV and by watching for both the leaﬂets
“lapping” into the clip arms or the paddles.
 Pacing, and breath-hold may be necessary in some cases when simultaneous
grasping is difﬁcult.
 Ensuring adequate leaﬂet insertion is critical, and must be performed in
multiple two-dimensional views 0  , 30  , 60  , 90  and 150
 Both leaﬂets should appear taut over the clip arms or the paddles with
minimal lift.
 Independent grasping of the leaﬂets are now possible with both the devices
and 2D LVOT or zero degree view of the MV can be used to optimize the
grasp.

Assessment of MR reduction

 2D TEE CFD in all the standard
views
 PV ﬂow pattern
 PW of the LVOT from transgastric
view
 3D TEE CFD

 2D CFD is helpful, but residual MR is often challenging to assess reliably.
Quantitative methods (VC and PISA EROA) have not been validated in the
presence of split MR jets.
 Change pulmonary vein pattern is also a good indicator of reduction in MR.
Disappearance of ﬂow reversal and restoration of any degree of systolic
forward ﬂow is the most concrete evidence of signiﬁcant reduction of MR.
Improvement of blunted systolic forward ﬂow is another positive sign of
signiﬁcant MR reduction but this is more subjective. There have this been
some attempts to quantify the pulmonary vein ﬂow improvement but has not
been independently validated nor widely used.
 3D TEE CFD can be used to compute mitral and aortic stroke volume from
which RV and RF can be obtained. This need further validation.
 Computing LV stroke volume from PW of the LVOT from the 2D TEE transgastric view of the LVOT and comparison to baseline may also be a helpful
indicator of reduction of MR, although this is not always reliable.
 Finally, evaluation of residual MR with clips arms loosened and retightening
is useful to conﬁrm insertion of both leaﬂets. Also, repositioning the clip may
be necessary if the MR reduction is not adequate or if there is signiﬁcant jet
either side of the clip. In the latter instance an additional clip may be
necessary.

Exclusion of signiﬁcant mitral stenosis

 2D TEE PW
 2D TEE transgastric planimetry of
MVA
 3D TEE MVA

 Transmitral gradient measurement is essential to evaluate the results. If a
second device is necessary and the transmitral gradient is high, consider
change the ﬁrst clip position
 Optimal result: transmitral gradient <4 mm Hg
Continued on the next page
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T A B L E 5 Continued

Step

Examination of the atrial septum to
assess the residual IAS shunt,
pericardial effusion

Tools

Tips

 2D CFD TEE to examine IAS shunt
 Direct measurement of the IAS
defect using 3D TEE
 2D TEE to exclude pericardial
effusion

 A large IAS shunt may require device closure.
 Change in size of pericardial effusion or appearance of new effusion should
trigger a search for cause and close follow-up.

*Height <4 cm may be acceptable when the leaﬂets are signiﬁcantly retracted with coaptation deeper in the LV; >4.5 cm is often necessary when there is ﬂail leaﬂet pathology, especially medial ﬂail
pathology. †3D TEE/ﬂuoroscopy fusion may play a role, facilitating the correct access site.
2D ¼ 2-dimensional; CDS ¼ clip delivery system; CFD ¼ color ﬂow doppler; EROA ¼ effective regurgitant oriﬁce area; IAS ¼ inter-atrial septum; LA ¼ left atrium; LUPV ¼ left upper pulmonary vein;
LVOT ¼ left ventricular outﬂow tract; MR ¼ mitral regurgitation; MV ¼ mitral valve; PFO ¼ patent foramen ovale; PISA ¼ proximal isovelocity surface area; PW ¼ pulsed wave doppler (Doppler);
RF ¼ regurgitant fraction; RV ¼ regurgitant volume; SGC ¼ steerable guide catheter; TEE ¼ transesophageal echocardiography; VC ¼ vena contracta; VTI ¼ velocity time integral.

transthoracic echocardiography (TTE) to grade the

TTE ﬁndings are equivocal, such as in the case of

severity of MR, establish the anatomic basis of MR, to

moderate MR and LV dilation, further imaging with

assess LV and RV size and function, evaluate

TEE or cardiac magnetic resonance (CMR) should be

tricuspid and aortic valves, and estimate right heart

considered. CMR has the advantage of providing ac-

pressures. When TTE images are inadequate or when

curate assessment of LV volumes, ejection fraction,

T A B L E 6 Procedural Imaging Guide for Transfemoral Direct Annuloplasty (Cardioband)

Step

Tools

Tips

Baseline imaging

2D and 3D TEE

 Standard 2D and 3D imaging of the MV, MR, and 2D imaging right and left heart.
 VTI of the PW of the LVOT from 2D TEE transgastric view as an estimate of LV
stroke volume.
 3D CFD to compute aortic and mitral stroke volume from which RV and RF may be
calculated.

Safe and optimal site of trans-septal
puncture

 2D TEE Bicaval view (90 -120 )
superior-inferior orientation
 2D TEE Short-axis view (30 -45 )
anteroposterior orientation
 2D TEE 4-chamber view (0 -20 )
determine the height above the
MV
 3D TEE/ﬂuoroscopy fusion*






Placement and navigation of the
trans-septal sheath and guide
catheter in the LA

 3D TEE LA view/en face MV view
 Fluoroscopy, LAO
 3D TEE/ﬂuoroscopy fusion

 Aid in the assessment of the general orientation of the TSS and GC, gross tip
positioning and angulation of GC.

Implant catheter placement and
deployment of anchors

 2D TEE biplane
 3D TEE LA view/en face MV view
and MPR
 Fluoroscopy (RAO)
 3D TEE/ﬂuoroscopy fusion

 The 2 orthogonal planes show the intersection of the tip of the catheter, which
would be in contact with tissue along the annulus. One plane is cutting the mitral
valve through its middle (the primary view in 2D TEE or the A-plane when MPR
from 3D TEE en face view of the MV is used). The other plane is tangential to the
native annulus in that given point (the orthogonal plane, X-plane or any plane
when MPR from 3D TEE is used).
 In the ﬁrst plane the distance from the hinge point, the implant angle (angle
between catheter and valve plane), and any interaction with adjacent structures
such as vessels or calciﬁcation is seen.
 In the tangential plane the retro-angle (the angle between the catheter and the
already implanted anchors will be seen). Anchor deployment is visualized in a
RAO ﬂuoroscopic view.
 Pull test is visualized in the same 2D TEE planes used for anchor placement, in
addition to a RAO ﬂuoroscopic view.
 Following conﬁrmation of the location of the anchors with 2D/3D TEE, coronary
angiography is performed to rule out the risk of circumﬂex damage. The RAO
ﬂuoroscopic view will show the ﬁnal positions of the anchors and implant fabric
release.

Implant catheter removal and SAT
insertion

 3D TEE LA view/en face MV view
 Fluoroscopy

 The implant is disconnected from the IDS, the SAT is inserted and connected to
the adjustment spool of the implant.

Implant size adjustment/cinching.

 2D TEE CFD
 Fluoroscopy
 3D TEE LA view/en face MV view

 After SAT connection, the implant is contracted by clockwise rotation of the
adjustment roller. The reduction of MR severity is assessed by CFD monitoring
under beating heart conditions. When the appropriate implant size has been
reached, the SAT is disconnected leaving the implant with the desired degree of
contraction.

Sharp tenting in both views should be seen prior to the puncture
Localization: superiorly and posteriorly in the IAS with a height of >3.5 cm.
The puncture (tenting) must be on top of the posteromedial commissure.
If the trans-septal puncture is not optimal consider repuncture to facilitate
proper orientation of the TSS relative to the mitral coaptation plane; avoid PFO.

CFD ¼ color ﬂow doppler; GC ¼ guide catheter; IAS ¼ inter-atrial septum; IDS ¼ implant delivery system; LA ¼ left atrium; LAO ¼ left anterior oblique; LV ¼ left ventricle; LVOT ¼ left ventricular outﬂow
tract; MPR ¼ multiplanar reconstruction; MR ¼ mitral regurgitation; MV ¼ mitral valve; PFO ¼ patent foramen ovale; PW ¼ pulsed wave doppler; RAO ¼ right anterior oblique; RF ¼ regurgitant fraction;
RV ¼ regurgitant volume; SAT ¼ size adjustment tool; TEE ¼ transesophageal echocardiography; TSS ¼ trans-septal sheath; VTI ¼ velocity time integral.
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T A B L E 7 Procedural Imaging Guide for Transfemoral Indirect Annuloplasty (CARILLON MCS)

Step

Tools

Tips

Baseline Imaging

 2D TEE or TTE

 Standard 2D imaging of the MV and MR.

Coronary sinus access

 Fluoroscopy, venous phase of RCA
angiogram to identify the CS ostium

 The CMCS delivery catheter, diagnostic catheter, and soft tip guidewire are placed in
the CS. The delivery catheter and the diagnostic catheter are advanced to the junction of the GCV and AIV.

Implant target location and
implant size selection

 Fluoroscopy, LAO/caudal or AP/caudal
and RAO/caudal

 Placement and advancement of the sizing catheter within the delivery catheter to
along the distal ends of both.
 Coronary arteriograms and venogram with the sizing catheter within the delivery
catheter.
 Average diameter measurement over 2 cm zone of the GCV and CS for the distal and
proximal anchor target site, respectively.
 Implant size is selected based on the available vein length between the GCV/AIV
junction and the CS ostium, vein diameters and geometry and arterial size and
proximity to the vein. All of these are evaluated from the ﬂuoroscopic images.

Device Implantation

 Fluoroscopy, LAO/caudal or AP/caudal
and RAO/caudal
 2D TEE or TTE

 The implant catheter is advanced to the distal end of the delivery catheter and the
distal anchor is deployed at the target site and locked. Arteriograms may be done to
assess impact on coronary arteries.
 The delivery catheter is then pulled back and tension applied to the place the anchor
at the proximal site. The anchor is then locked in position.
 The target sites are marked on the screen with the ﬂuoroscopic pictures previously
obtained (described above).
 2D CFD may be used to assess the MR reduction during the placement of the anchors
but this is optional since the size of the implant and the locking of the anchors determines the magnitude of the reshaping of the annulus. For a given size of the
implant this is ﬁxed. However, echo may be useful to monitor for complications.

AIV ¼ anterior interventricular vein; AP ¼ anteroposterior; CMCS ¼ Carillon mitral contour system; CS ¼ coronary sinus; GCV ¼ great cardiac vein; LAO ¼ left anterior oblique; MR ¼ mitral regurgitation;
MV ¼ mitral valve; RAO ¼ right anterior oblique; RCA ¼ right coronary artery.

and the presence of scar tissue or myocardial ﬁbrosis

also be used to size the ring or the band, but this is

as well as quantitative assessment of MR severity.

less reliable than 3D TEE. The predictive value of 3D

Pre-procedural TEE can also corroborate MR severity

TEE is only a guide and does not replace the sizing

and clarify MV pathology, including the degree of

done intraoperatively. However, this information is

leaﬂet or annular calciﬁcation which may inﬂuence

valuable if it is available pre-procedure for the sur-

treatment strategy.

geon to compare to intraoperative sizing, which is

There are 2 important factors which determine the

done differently by different surgeons (28). The other

reparability of degenerative MV disease: the presence

quantitative data which may be helpful to the sur-

of signiﬁcant leaﬂet or annular calciﬁcation and

geon is the P2 height; if this is >20 mm, reduction of

complex degenerative disease (such as anterior MV

this height is essential to prevent post-operative SAM

leaﬂet prolapse, bileaﬂet prolapse, or Barlow disease)

of the MV and LVOT obstruction (9). Video 3 illus-

(21,22). Signiﬁcant annular calciﬁcation impacts the

trates this systematic approach to information gath-

possibility or the durability of the repair. The pres-

ering from a pre-procedural TEE. Also, in Video 2

ence of complex degenerative anatomy in the hands

(Slides 19 to 24) assessment of possible presence of

of less experienced surgeons (especially in centers

clefts or indentations and mixed mechanisms for MR

performing <23 MV surgeries per year) can lead to

are shown.

suboptimal repair or MV replacement and also affects

Beating heart chordal implantation MV repair. This

the durability of repair compared to isolated P2 repair

technique involves restoration of leaﬂet coaptation

(23–26). Detection of indentations and clefts in the

through implantation of artiﬁcial chords. In the

MV leaﬂets using 3D imaging and CFD is an important

transapical technique (Video 4), the length of the

anatomic consideration in a patient being considered

chords

for MV intervention (27). A prior knowledge of these

coaptation-guided reduction in MR by TEE CFD im-

anatomic factors is always helpful for the surgeon.

aging, followed by anchoring the chords at the LV

are

adjusted

to

yield

optimal

leaﬂet

Also, quantitative 3D TEE can be used to measure A2

apex (29–31). However, clinical trials using the

height, intertrigonal distance, and total annular

transapical approach have been paused with an un-

perimeter size. These measurements can predict the

certain future. However, the principle of trans-

size of the annuloplasty ring or band. Of these pa-

catheter chordal implant-based MV repair is being

rameters, A2 height and intertrigonal distance are

explored with newer generation devices. These

most commonly used by surgeons during the opera-

technologies are very early in their development and

tion. Additionally, intercommissural distance can

clinical evaluation. Detailed description of their
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T A B L E 8 Procedural Imaging Guide for Transfemoral Ventricular Repair (AccuCinch)

Step

Tools

Tips

Baseline imaging

 2D TEE
 3D TEE

 Standard 2D imaging of the MV and MR.
 3D TEE is optional and not necessary for the procedure guidance

Retrograde LV access and placement
of guide catheter

 Fluoroscopy
 2D TEE (transgastric short-axis of
the MV)

 The guide is placed underneath the antero-lateral mitral commissure
 The guide provides support for the subsequent delivery system to access the LV
and sub-annular mitral space.

Placement of the NavCath and
guidewire in the mitral
subannular space

 Fluoroscopy
 2D TEE of the AV
 2D TEE (transgastric short-axis of
the MV)

 The NavCath facilitates atraumatic placement guide wire around the subannular
space below the mitral valve, between the chordae tendineae and the endocardial wall.
 The NavCath acts as a support catheter to the guidewire as it navigates the LV
circumferentially behind the chordae tendineae in the subannular space below
the MV leaﬂets.
 The guidewire is extended beyond the tip of the NavCath and the pair is advanced
circumferentially around the mitral annulus and then antegrade across the aortic
valve and into the descending aorta. The NavCath is then removed.
 Echocardiography of the AV to assess presence and severity of AR

Implant delivery

 Fluoroscopy
 2D TEE (transgastric short-axis of
the MV)
 2D TEE of the AV

 The TracCath provides a template for the delivery catheters to place Anchors and
Sliders at ﬁxed, predetermined intervals.
 Tracath is advanced over the guidewire so that the distal end is below the
posteromedial commissure of the mitral valve (P3), and the entire TracCath lies
behind the chordae tendineae and against the endocardial wall.
 By aligning the windows of outer and inner Tracath the positioning of the delivery catheter, and the anchor deployments are precisely controlled.
 Delivery catheters place anchors into tissue and sliders between each anchor.
 The anchor delivery depth is guided by a guidewire that exits the delivery
catheter proximal to its tip and lies against the endocardium providing a radiopaque boundary marker of the endocardial wall; also the anchors are echobright and can been seen in the myocardium.
 Echocardiography of the AV to assess AR.

Implant cinch

 Fluoroscopy
 2D TEE (transgastric short-axis of
the MV) with CFD for MR
 2D TEE mid-esophageal standard
views CFD of the MR
 2D TEE of the AV

 Trac Cath is then removed and Cinch device advanced to the LV.
 The anchors are cinched with removal of the space between the sliders
 When adequate reduction in MR is seen, the anchors are locked and the cable cut
to complete the device implant.
 Echocardiography to assess AR.

AR ¼ aortic regurgitation; AV ¼ aortic valve; CFD ¼ color ﬂow doppler; LV ¼ left ventricle; MR ¼ mitral regurgitation; MV ¼ mitral valve; TEE ¼ transesophageal echocardiography.

present utility is not meaningful, but the optimal

these devices also recreate the coaptation reserve by

pathoanatomy for this procedure may be isolated

permanently opposing the leaﬂets along the free

posterior leaﬂet prolapse or ﬂail. Thus 2D and 3D TEE

edges and the rough zones. TTE and TEE are the

may be key to accurately describing all primary and

mainstays for planning the edge-to-edge leaﬂet repair

secondary MV lesions (such as clefts, commissural

procedure. TTE is valuable for identifying the cause

abnormalities, and tethering of the anterior MV

of MR and evaluate its severity. It is also an important

leaﬂet) to ensure appropriate patient selection.

test to recognize factors that may predict unfavorable

repair. MitraClip

clinical beneﬁts, even if the procedural outcome was

(Abbott) is the most widely used approved device for

optimal, such as the presence of severe tricuspid

percutaneous repair of the MV. The Pascal device

regurgitation

(Edward Lifesciences, Irvine, California) is also

procedural 2D and 3D TEE are critical to further

Transfemoral

edge-to-edge

leaﬂet

or

RV

systolic

dysfunction.

Pre-

approved in Europe for similar indications (it is

deﬁne the anatomy with an emphasis on ﬁnding

currently undergoing clinical studies in the United

anatomic characteristics, which may either preclude

States). Both devices are edge-to-edge leaﬂet repair

or complicate the procedure (12, 32–34). In some

systems. The current indications for these devices are

cases, pre-procedural TEE is used to quantify the MR

for symptomatic moderate to severe and severe

in place of an inadequate TTE (34,35). Pre-procedural

degenerative and functional MR. After guideline-

TEE is also useful to establish whether the MV is

mandated medical therapy, persistent heart failure

imaged optimally in the supine position in addition to

and consideration of coronary revascularization and

the left lateral decubitus position. Sometimes, left tilt

cardiac synchronization therapy are necessary before

of the patient is helpful, but this does not always

resorting to transcatheter therapy in functional MR.

guarantee adequate visualization of the MV.

The Alﬁeri Stitch surgical principle, which creates a
dual-oriﬁce MV, forms the basis of these devices. But

Notwithstanding

these

reasons,

routine

pre-

procedural TEE is unnecessary, especially when there
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T A B L E 9 Procedural Imaging Guide for Transapical and Transfemoral Mitral Valve Replacement

Tools

Tips

Optimal transapical access
site localization

Step

 2D TEE Intercommissural view (60o )
for medial-lateral, and LVOT view
(135 o -150o ) for anteroposterior
orientation
 ﬁnger poke for access site localization

 X-plane imaging (typically 60 and 135 -150  ) is used to determine whether the
access has an optimal orientation relative to the antero-posterior and medial- lateral
planes relative to the MV
 The trajectory should avoid the RV apex, septum, and the papillary muscles.
 Preprocedural CT of the chest and the heart helps to identify the best access site with
the optimal trajectory

Sheath positioning

 2D TEE inter-commissural view (60o )
and LVOT view (135o -150o )
 3D LA view/en face MV view
 Fluoroscopy

 Once a standard 6-F sheath is inserted, a balloon catheter is advanced into the LA,
guided by echo to conﬁrm no entanglement with the sub-valvular apparatus. Next
a device speciﬁc sheath is inserted.
 An enface 3D TEE view is used to position the delivery system at A2/P2 in the mitral
oriﬁce

Valve implantation

 2D TEE Inter-commissural view (60o )
and LVOT view (135o -150o )
 3D LA en face MV view
 Fluoroscopy

 Intrepid: Once the valve is in proper position, rapid pacing and breath hold is
necessary to expand the brim of the Intrepid (under ﬂuoroscopy and 2D X-plane).
 3D TEE en face MV view helps to align the open brim with annulus and ensure that
there are no indentations of the brim.
 Final deployment of the valve is completed under rapid pacing and breath hold. The
device is then retracted to the 6 mm target. The implant is deployed with a ﬁnal
inﬂation. Final positioning is conﬁrmed on 2 D TEE.
 Tendyne: The prosthesis is introduced through the sheath, partially unsheathed in
the LA aligned with the aorto-mitral continuity using 3D TEE enface MV view and
ﬂuoroscopy. On 2D TEE X-plane imaging, the prosthesis is retracted until the cuff of
the device rests on the ﬂoor of the LA followed by intra-annular deployment. A
braided, high molecular weight polyethylene tether is attached to an epicardial pad,
and the tension of the tether is adjusted after deployment to optimize the seating of
the prosthesis.
 3D TEE enface MV view is especially useful for determining rotational alignment of
the device with the annulus.

Final evaluation

 2D CFD /3D CFD
 2D TEE intercommissural view (60o )
and LVOT view (135 o -150o ) and other
standard MV views
 3D LA en face MV view and long-axis
views of the LVOT/neo-LVOT
 2D TEE transgastric view of the LVOT/
neo-LVOT
 Fluoroscopy

 CFD in multiple 2D TEE views are used to examine any MR (TVL or PVL), and the 2D
TEE LVOT view is especially optimal to look for LVOT/neo-LVOT obstruction.
 3D TEE CFD is useful to establish the presence and location of PVL.
 Imaging in multiple 2D TEE views and 3D TEE enface MV view is essential to ensure
that the prosthesis is fully expanded, well seated and that MV oriﬁce is nearly
circular.
 CW of the MV inﬂow for mean MV gradient is obtained from one of the midesophageal views 2D TEE view of the MV
 PW/CW Doppler of the LVOT/neo-LVOT is performed in the deep transgastric view of
the LV and LVOT.
 3D CFD in the long-axis orientation can be useful to look for CFD aliasing in the LVOT/
neo-LVOT, and the neo-LVOT area can be measured from the same data.
 If the function of the prosthesis is not acceptable, or LVOT obstruction occurs, the
valve can be recaptured, and redeployed or fully retrieved (Tendyne only).
 Final position is check under ﬂuoroscopy

CFD ¼ color ﬂow doppler; CW ¼ continuous wave (Doppler); LA ¼ left atrium; LVOT ¼ left ventricular outﬂow tract; MV ¼ mitral valve; PVL ¼ paravalvular leak; PW ¼ pulsed wave (Doppler); RV ¼ right
ventricle; TVL ¼ transvalvular leak.

is good quality TTE, there are no apparent concerns of

remodeling. Type I (annular dilation/deformation)

high-risk anatomy, and the interventional team has

and Type IIIB (symmetrical leaﬂet tethering) are the

sufﬁcient experience in this procedure. Cardiac

most suitable for this therapy. However, CT is

computed tomography (CT) is rarely needed for

essential for planning the procedure. The key factors

planning the edge-to-edge leaﬂet repair procedure.

in planning this procedure are: 1) the site for a trans-

Table 2 provides a guide to the selection of patients

septal puncture; 2) annulus size; 3) the presence,

for the edge-to-edge leaﬂet repair procedure based on

location, and extension of annular calciﬁcations; 4)

MV anatomy. Video 2 shows the surgical and echo-

the angle of anchor deployment; 5) the distance from

cardiographic anatomy of these abnormalities.

the hinge point; 6) the distance from the circumﬂex

Transfemoral
(Edwards

direct

annuloplasty. The

Lifesciences)

is

an

Cardioband

artery (minimal distance >2.5 mm); 7) the quality and

incomplete

thickness

adjustable surgical-like Dacron band delivered from

of

annular

tissue

(minimal

thickness

>4 mm); 8) the anatomy of the annulus; 9) the LA size

the trans-septal approach. It is implanted in the

and shape: “shelf-like” or “cliff-like”; 10) the ex-

posterior annulus from anterolateral to poster-

pected ﬂuoroscopic projections; and h) the 3D pre-

omedial commissure (36). TTE forms the basis for

view of the system position (Video 5).

quantifying MR, determining the mechanism of MR

Transfemoral indirect annuloplasty. Planning for a cor-

and assessment of LV and RV size and function. Pre-

onary sinus or great cardiac (CS/GCV) vein-based de-

procedural 2D and 3D TEE are essential to assess MV

vice (Carillon Mitral Contour System [CMCS]; Cardiac
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Dimensions Carillon, Kirkland, Washington), which
reshapes the mitral annulus, currently does not
require procedure-speciﬁc imaging (37,38). TTE is
done to assess the severity of MR and to establish a
baseline. If theres is a recent history of atrial ﬁbrilla-

T A B L E 1 0 Essential Elements to Assess During Follow-Up

Imaging of Mitral Devices

Device
 Stability (dehiscence, dislodgement, fracture, detachment)
 Leaﬂet motion (transcatheter mitral valve replacement)

tion, a TEE is indicated to exclude a left atrial

 Masses: vegetation, thrombus

appendage clot. However, in the CARILLON Mitral

Hemodynamics

Contour System for Reducing Functional Mitral

 Residual mitral regurgitation: severity (VC)

Regurgitation, (REDUCE-FMR) study, approximately

 Residual mitral regurgitation: TVL, PVL

15% of the patients randomized to the treatment arm
did not have the device implanted. Whether this was

 Mean gradient
 Pulmonary vein ﬂow pattern

due to unfavorable CS/GCV results or left circumﬂex

 Severity of tricuspid regurgitation and right ventricular systolic
pressure

artery (LCX) anatomy is unclear, but this may in the

Chamber size and function

future necessitate CT to assess the venous and coro-

 Left ventricular stroke volume and ejection fraction

nary artery anatomy before the procedure (39–42).
Other device-speciﬁc exclusions are the presence of
prosthetic MV or ring (which may be available by
history) and mitral annular calciﬁcation, which is

 Right ventricular systolic function
 Left ventricular remodeling (dimensions, volumes)
Pericardial effusion
PVL ¼ paravalvular leak; TVL ¼ transvalvular leak.

usually seen on TTE.
Transfemoral ventricular repair. Reducing the circumference of the posterior wall is another approach to

dysfunction and severe LV external end-diastolic

reducing MR, speciﬁcally functional MR. The Accu-

diameter (LVEDD >70) are currently excluded from

Cinch ventricular repair system (Ancora Heart, Sanat

TMVR.

Clara, California) is such a device in which implant

At present, pre-procedural 2D and 3D TEE are done

catheters are placed in the mitral sub-annular space

for 2 primary reasons. The ﬁrst reason is to assess the

via a transfemoral approach and retrograde LV access

MV apparatus qualitatively and quantitatively. The

(43). Several anchors are delivered into the posterior

second reason is to deﬁne the mechanism of MR

myocardium beginning at the P3 region and ending in

further. Also, TEE is useful to quantify the relation-

the P1 region. Cinching the anchors facilitated by

ship of the MV to adjacent structures, which deter-

sliders between the anchors reduces the size of the

mine the optimal procedural outcome. CT is used for

posterior LV wall and the mitral annulus. The critical

pre-procedural planning for transapical mapping,

imaging factors for planning this procedure include

mitral sizing, and assessing the patient-speciﬁc risk of

an assessment of the severity of MR, size, and func-

LVOT obstruction. It is important to note that these

tion of the LV and exclusion of signiﬁcant MV pa-

indices are based on current experience in <500 cases

thology

usually

of human implants and predominantly for 2 devices.

accomplished by pre-procedural TTE unless it is

Our understanding of the factors, which are critical to

suboptimal, in which case, TEE is done to evaluate

ensure optimal procedural outcome after TMVR, will

these factors. CT is done mainly to assess adequacy of

continue to evolve. Furthermore, trans-septal TMVR

peripheral vascular access (20-F is required), but also

may mitigate some of these issues with the trans-

done to examine LV trabeculae that may pose chal-

apical

lenges for anchor placement.

Tables 3 and 4 summarize the critical points for the

Transapical and transfemoral TMVR. TMVR of the native

imager to consider when planning transapical TMVR

MV for MR has 2 primary routes of access: transapical

and the relative utility of various modalities for

and trans-septal. Planning of TMVR of the native MV

assessing these factors (19,49–55). Video 6 illustrates

for MR requires a systematic approach to address

these factors.

factors intrinsic to the MV apparatus and to those

PROCEDURAL GUIDANCE. Surgical MV repair. Procedural

associated with the relationship of the MV to the

guidance for surgical MV repair is centered around a

adjacent structures. Currently, echocardiography and

comprehensive baseline intraoperative TEE to estab-

as

the

cause

of

MR.

This

is

method

while

bringing

new

challenges.

CT are the key modalities for planning TMVR (44–48);

lish (or conﬁrm ﬁndings in the pre-preprocedural

CMR may have a selective role in routine practice. A

TEE) the anatomic basis of the MR. Also, assessment

comprehensive TTE is central to establish the cause,

of LV and RV function and evaluation of the degree of

mechanism, severity of MR, and the impact of MR on

TR and measurement of the tricuspid annulus spe-

myocardial

ciﬁcally are essential among other routine examina-

function.

Patients

with

severe

left

ventricle ejection fraction (LVEF <25% to 30%)

tion

protocols.

Post-operative

TEE

examination
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C E N T R A L IL L U ST R A T I O N An Interventional Imaging Paradigm for Mitral Regurgitation
Primary, Secondary, and
Mixed Mitral Regurgitation

Imaging Modalities and Technologies
2D/3D TTE and TEE, CMR

Etiology, Mechanism,
Grading

Imaging Pathway

124

Pre-procedural Planning

Candidate for Surgery

Candidate for Transcatheter Intervention

2D/3D TTE and TEE

2D/3D TTE and TEE, CT, Computational Modeling,
3D Printing and Artificial Intelligence*

Repair

Intra-procedural Guidance
and Monitoring

Post-procedural follow-up

Replacement

Leaflet Repair
Chordal Implantation

Annuloplasty
Ventricular Repair
Replacement

2D/3D TTE

2D/3D TEE,
Fluoroscopy,
Fusion Imaging

2D/3D TTE
2D/3D TEE*

2D/3D TTE
2D/3D TEE*
CT*

Gheorghe, L.L. et al. J Am Coll Cardiol Img. 2021;14(1):112–27.

The elements of a systematic imaging pathway are shown on the left. The imaging modalities which best match the steps in the imaging
pathway are shown on the right. An important aspect of this approach is that it emphasizes the role of imaging in decision making with
respect to therapy selection (surgery vs. transcatheter) and the Type of intervention within the chosen therapy. Among transcatheter options,
a combination of Types of interventions may be possible in the future, to maximize the beneﬁt. *These imaging tests are not routine and
only done when indicated.

includes locating and detecting intracardiac air when

5) exclusion of signiﬁcant mitral stenosis; and 6) ex-

coming off cardiopulmonary bypass and assessment

amination of the atrial septum to assess the residual

of the integrity of the MV repair. If MR is present, its

IAS shunt and the need for closure (48,56,57). The

severity and origin must be investigated. An evalua-

procedure guidance for the MitraClip and Pascal de-

tion of the LV and RV function is also essential to

vices is similar. The critical steps in the procedure and

ensure that there has not been a signiﬁcant change

the imaging tools best suited to guide these steps are

from baseline. The example in Video 7 illustrates

shown in Table 5, and illustrative cases are shown in

these factors shows the importance of this approach

Videos 8 (MitraClip) and 9 (Pascal device images,

both for baseline and immediate post-repair TEE.

courtesy of Dr. D. Arzamendi, Barcelona, Spain).
the

If intracardiac echocardiography (ICE) is used to

MitraClip or Pascal device procedure, a comprehen-

guide the procedure, it is best to combine TEE and ICE

sive intraprocedural baseline TEE imaging is done in

or TTE and ICE (if TEE is impossible). This is because,

the absence of quality pre-procedural TEE. If a recent

although 2D ICE provides the best image quality,

complete TEE is available, baseline imaging may only

single-plane imaging limits its utility. Furthermore,

focus on the key parameters shown in Video 8. The

although imaging the MV from the right heart (RA or

crucial steps of the procedure are: 1) safe and optimal

the RV outﬂow tract) is possible, trans-septal ICE

site of the trans-septal puncture and placement of the

imaging may be necessary to visualize the MV leaﬂets

steerable guide catheter; 2) safe steering of the device

adequately. Video 10 shows an example of MitraClip

delivery system within the LA and its alignment

procedure guided by TEE and 2D single-plane ICE.

perpendicular to the mitral coaptation plane; 3)

Volume ICE, potentially, overcomes the limitation of

adequate leaﬂet insertion for creation of the tissue

2D ICE and may be used for procedural guidance but

bridge during grasps; 4) assessment of MR reduction;

the experience is limited to few case reports of a very

Transfemoral

edge-to-edge

leaﬂet

repair. For
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few cases (58–60). With further development in the

and optimal positioning of the sheath in the LA;

technology in the future, ICE may offer an alternative

3) guiding the optimal placement and full deployment

to TEE. An alternative to TEE may be necessary,

of the valve; 4) checking the stability and functioning

especially when imaging the MV requires frequent

of the valve; 5) assess for the presence and location of

probe manipulation and positioning, especially in

TVL and PVL; and 6) examine the LVOT/neo-LVOT for

prolonged

circumstances,

obstruction. The imaging tools best suited to guide

esophageal injury may be more common than previ-

these steps are shown in Table 9. Videos 14 and 15

procedures.

In

these

ously thought (61).

show examples of these steps.

Transfemoral direct annuloplasty. The implantation of

FOLLOW-UP. Comprehensive TTE is the key test in

the Cardioband (Edwards Lifesciences) is a step-by-

following up of these devices. Even when TTE may

step procedure. Each step is repeated for the num-

not be optimal to visualize the devices, the hemody-

ber of total anchors to be implanted and consists of

namic information obtained by spectral Doppler is

the following phases: 1) trans-septal puncture; 2)

invaluable. TEE is indicated when TTE is not optimal

positioning the delivery system at the optimal loca-

and in speciﬁc circumstances such as suspected

tion for anchors moves to a possible implant position;

infection; or thrombus; or when the origin of residual

3) deployment of anchors when the position and the

MR needs clariﬁcation or for planning for further

angulation of the delivery system is optimal; and 4)

intervention (65). Exceptionally, CT or CMR may be

pull test to assess the resistance of the anchors, and

necessary to resolve speciﬁc questions. Table 10 lists

release of the anchor if the pull test is successful (62).

the important aspects of the follow-up assessments.

These steps are repeated for deployment of each an-

Videos 16, 17, 18, 19, and 20 show examples of the

chor, and 2D or 3D TEE and ﬂuoroscopy guides each of

essentials

of

follow-up

echocardiography

and

these steps (Table 6, Video 11).

selected complications of some of the interventions.

Transfemoral indirect annuloplasty. The CMCS system

The frequency of follow-up imaging is not standard-

consists of: 1) an implant intended for permanent

ized, but currently, it is standard to assess the pro-

placement in the CS/GCV; 2) A catheter-based de-

cedural outcome before discharge and at 1, 3, and

livery system which consists of a curved CMCS de-

6 months. Routine testing after 6 months is usually

livery catheter and a handle assembly; and 3) a sizing

done at 1 year. If there are suspected or known com-

catheter used to measure the CS/GCV for implant size

plications, testing can be done more frequently.

selection. The implant is attached to the handle assembly and delivered through the CMCS delivery

CONCLUSIONS

catheter to the coronary vein along the posterolateral
aspect of the mitral annulus. The implant is designed

Interventional imaging plays an integral role in the

to reshape the mitral annulus to reduce annular

planning,

dilation and mitral regurgitation. Fluoroscopy is the

terventions (Central Illustration). Qualitative and

crucial imaging modality to guide this procedure,

quantitative imaging performed by interventional

with TTE or TEE either optional or used only for

imaging provide critical insights into the pathoa-

baseline and post-procedure assessment of the MR

natomy and physiology of the abnormalities, which

and LV (40). Echocardiography is necessary to detect

is essential for developing an intervention plan that

any

is speciﬁc to the abnormality in each individual.

complications

such

as

pericardial

effusion

guidance,

follow-up

in-

Newer

modeling, 3D printing, and artiﬁcial intelligence

ular repair system consists of an implant and delivery

show promise in further improving planning, selec-

system. There are 3 critical procedural steps: 1) LV ac-

tion, and predicting outcomes of transcatheter MV

cess; 2) implant component delivery; and 3) implant

interventions (66).

Table 8 and an example is shown in Video 13.
Transapical and transfemoral MV replacement. TEE and
ﬂuoroscopy are used to guide transapical TMVR (47,

as

MV

Transfemoral ventricular repair. The AccuCinch ventric-

modalities to guide this procedure as described in

such

of

(Table 7, Video 12).

cinch (43). Fluoroscopy and 2D TEE are the key imaging

technologies

and

computational
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